Organic Process Research & Development · 2005 · 23 citations · 9 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryNeuropharmacologySynthetic Medicinal ChemistryChiral ChromatographyChromatographyDopaminergic PharmacologyNeurodegenerative Disease PharmacotherapyParkinson DiseasePotency OptimizationAnalytical Chiral ChromatographyChiral High-performance Liquid ChromatographyDiastereomeric Salt FormationMedicinal Chemistry ApplicationsParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyPreferred Orientation
This article describes the development and optimization of chemical reactions and subsequent preparation of the API LY503430 under cGMPs to fund first human dose (FHD) clinical evaluation as a potential therapeutic agent for Parkinson's disease. Reasons and rationale are presented for changes in solvents and reagents. One of the major developments presented here is the replacement of a chiral chromatography with a diastereomeric salt resolution. This article also discusses a preferred orientation issue with LY503430 which complicated the XRPD analysis.
9
Organoborates in new synthetic reactions
Akira Suzuki · Accounts of Chemical Research · 1982 · 422 citations
Aryl couplings with heterogeneous palladium catalysts
Guy Marck, A. Villiger, Richard Buchecker · Tetrahedron Letters · 1994 · 191 citations
Tracey K. Murray, Katherine Whalley, Christine S. Robinson et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 106 citations
Paul L. Ornstein, Dennis M. Zimmerman, M. Brian Arnold et al. · Journal of Medicinal Chemistry · 2000 · 76 citations · Full text